A 58-year-old man with essential hypertension and type 2 diabetes mellitus is started on an antihypertensive agent. After 3 weeks, he develops a persistent dry cough, and serum creatinine rises from 1.0 to 1.4 mg/dL. Which is the most common cause of acute renal function deterioration in this clinical scenario?

## Acute Renal Function Decline with ACE Inhibitor in Diabetic Patient ### Clinical Context: ACE Inhibitor-Induced Renal Dysfunction The combination of **dry cough** (classic ACE-I side effect) + **acute rise in creatinine** in a diabetic patient points to **ACE inhibitor use**. The mechanism of renal function change is critical. ### Why Efferent Arteriolar Vasodilation Occurs **Key Point:** ACE inhibitors block angiotensin II formation, which preferentially vasodilates the *efferent* arteriole of the glomerulus. This reduces intraglomerular pressure and glomerular filtration rate (GFR). ### Pathophysiology ```mermaid flowchart TD A[ACE Inhibitor administered]:::action --> B[Blocks ACE enzyme]:::action B --> C[↓ Angiotensin II formation]:::outcome C --> D[Loss of efferent arteriolar vasoconstriction]:::outcome D --> E[↓ Intraglomerular hydrostatic pressure]:::outcome E --> F[↓ GFR / ↑ Serum creatinine]:::outcome F --> G{Reversible?}:::decision G -->|Yes - if mild| H[Continue with monitoring]:::action G -->|Yes - if severe| I[Discontinue ACE-I]:::action ``` ### Normal Renal Hemodynamics | Structure | Baseline Tone | Effect of Angiotensin II | | --- | --- | --- | | **Afferent arteriole** | Moderate | Mild vasoconstriction | | **Efferent arteriole** | High tone | **Strong vasoconstriction** | | **Net effect** | — | Maintains intraglomerular pressure | **High-Yield:** When ACE-I blocks Ang II, the efferent arteriole *dilates* (loses its tone), causing intraglomerular pressure to *fall* → GFR drops → creatinine rises. ### Expected Creatinine Rise - **Mild increase (< 30%):** Common, expected, usually reversible - **Moderate increase (30–50%):** Monitor closely; may continue if stable - **Severe increase (> 50%):** Discontinue; investigate for other causes (renal artery stenosis, acute interstitial nephritis) ### Why This Is "Most Common" in Diabetic Patients 1. **Diabetes + ACE-I = predictable GFR drop** due to baseline glomerular hyperfiltration 2. **Renal artery stenosis** (atherosclerotic) is more prevalent in diabetics → ACE-I can unmask bilateral RAS 3. **Proteinuria reduction** (beneficial long-term) requires initial GFR adjustment **Clinical Pearl:** A creatinine rise of 10–20% within 2–4 weeks of ACE-I initiation is *expected* and *reversible*. However, rises > 30% warrant investigation for renal artery stenosis (especially in diabetics with atherosclerosis). ### Management Strategy 1. **Baseline creatinine and K⁺** before ACE-I 2. **Recheck at 1–2 weeks** post-initiation 3. **If creatinine ↑ < 30%:** Continue; recheck at 4–6 weeks 4. **If creatinine ↑ > 30%:** Investigate for RAS; consider discontinuation 5. **Monitor K⁺ closely** (ACE-I reduces aldosterone → hyperkalemia risk) **Mnemonic:** **ACE-I Renal Effects = EFFERENT** - **E**fferent arteriolar vasodilation (loss of Ang II tone) - **F**iltering pressure drops - **F**unctional GFR declines - **E**xpected rise in creatinine (10–20%) - **R**eversible in most cases - **E**xcept if bilateral RAS or severe stenosis - **N**eed to monitor K⁺ (hyperkalemia risk) - **T**herapeutic benefit outweighs transient GFR drop (long-term renal protection) [cite:Harrison 21e Ch 297; KD Tripathi 8e Ch 40]